ZO1

Zonula occludens-1

Score: 0.517 Price: $0.52 Low Druggability Status: active Wiki: ZO1

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

609

DEBATES

3D Protein Structure

🧬 ZO1 — PDB 2JWE Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.33

Clinical Stage

Approved

Target Class

Structural Protein

Safety

0.20

Druggability Analysis

Drug Development0.65

Structural Tractability0.85

Target Class0.50

Safety Profile0.20

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (4 compounds)

1 Preclinical

Therapeutic Areas:

Neurodegeneration Rare Disease Musculoskeletal Immunology

Druggability Rationale: Structural proteins have moderate druggability when they contain regulatory domains. Approaches may include stabilizers, destabilizers, or modulators of post-translational modifications. Crystal structures available (12 PDB entries) supporting structure-based drug design. AlphaFold predicted structure available for computational screening.

Mechanism: Drugs targeting ZO1 typically work by stabilizing or modulating tight junction protein interactions, either by directly binding to ZO1 scaffolding domains or by regulating upstream signaling pathways that control ZO1 phosphorylation and localization. These approaches aim to restore blood-brain barrier integrity or modulate paracellular permeability depending on therapeutic context.

Drug Pipeline (4 compounds)

1 Preclinical

Known Drugs:

Occludin-based peptides (preclinical) — Blood-brain barrier dysfunction, neuroinflammation

JAM-C antagonists (research) — Tight junction modulation, inflammatory diseases

Claudin modulators (GlaxoSmithKline GSK1382716) (phase1) — Crohn's disease, inflammatory bowel disease

Zonula occludens toxin analogs (research) — Drug delivery enhancement, transepithelial transport

Structural Data:

PDB (12) ✓AlphaFold ✓Cryo-EM —

2JWE 2KXR 2KXS 2RCZ 3TSV+7 more

UniProt: Q07157

Binding Pocket Analysis:

Polymerization interface, PTM sites

🔮 Predicted Protein Structure (AlphaFold)

🔮 ZO1 — AlphaFold Q07157 Click to expand interactive 3D viewer

AI-predicted structure from AlphaFold EBI | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity considerations focus on tissue-specific expression patterns, as structural proteins often have essential roles in multiple organ systems.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

Completed

Total Enrollment

983

By Phase

NA: 5 · PHASE1: 1 · PHASE3: 1 · Unknown: 1

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain Not Yet Recruiting

PHASE3 NCT06797817 n=156

Alzheimer Disease (AD)

Interventions: tributyrin, Placebo

Sponsor: Universidad de Almeria | Started: 2026-06-01

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

Linked Hypotheses (0)

No linked hypotheses

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

...and 8 more

implicated in (1)

ZO1 → neurodegeneration

interacts with (3)

ZO1 → CLDN1

ZO1 → OCLN

ZO1 → MLCK

participates in (1)

ZO1 → Gut-brain axis / microbiome signaling

Debate History (0)

No debates yet

ZO1

3D Protein Structure

Druggability & Clinical Context

🔮 Predicted Protein Structure (AlphaFold)

Selectivity & Safety Considerations

3D Protein Structure

Clinical Trials (8)

Linked Hypotheses (0)

Linked Experiments (0)

Scoring Dimensions

Knowledge Graph (20)

activates (1)

associated with (1)

co discussed (13)

implicated in (1)

interacts with (3)

participates in (1)

Debate History (0)